MRTX

Mirati Therapeutics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, will participate at the Goldman Sachs 44th Annual Global Healthcare Conference 2023 on June 15 at 8:40 a.m. P.T. /...

Biotech Stock Roundup: MRTX Falls on Study Failure, LXRX Drug Wins Approval & More

Regulatory and pipeline updates from Mirati (MRTX) and Lexicon (LXRX) are in focus in the biotech sector....

Top Stocks for June 2023

Southwestern Energy, Mirati Therapeutics, and First Solar are top US stocks Russell 3000 in June 2023 for value, growth, and momentum, respectively....

Oppenheimer Sees Over 50% Gains in These 2 Stocks — Here’s Why They Could Soar

The shortened week kicked off with one big crisis averted for now. During the long weekend, an agreement was reached between President Biden and House Majority Leader McCarthy that should go toward re...

Mirati To Encore Compelling Clinical Data Demonstrating Adagrasib's Potential as a Targeted Treatment for KRASG12C-Mutated Advanced Solid Tumors at 2023 ASCO Annual Meeting

Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced presentations and posters to be shared at the 2023 American Society of Clinical Oncology (ASCO) An...

Disclaimer: The data contained in Super Surge website is not necessarily real-time nor accurate and may differ from the actual market data. Prices, volumes, ratios, charts and indicators are indicative and not appropriate for trading purposes. Super Surge doesn't bear any responsibility for any trading losses you might incur as a result of using this data.